CHMP Recommends Dovato Dispersible Tablets and Expanded Paediatric HIV-1 Indication – ViiV Healthcare
On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Dovato. The marketing authorisation holder for this medicinal product is ViiV Healthcare B.V.
The CHMP adopted a new indication associated with new Dovato 5 mg / 30 mg dispersible tablets, as follows:
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in children at least 3 months of age, weighing at least 6 kg to less than 25 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1).
The CHMP also adopted an extension to the existing indication for Dovato 50 mg / 300 mg film-coated tablets, as follows:
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults, adolescents and children weighing at least 20 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.




